Russia’s Secret Remedies For Vision, Hearing, & Skin Restoration

Nick Urban [00:00:05]:

What if some of the most incredible health transformation tools are actually staring us right in the face? And they’ve been around for years, decades, or in some cases even centuries, yet for some reason have largely been forgotten today. Welcome to body peak performance. I’m your host, Nick Urban, and today that is exactly what we are discussing. Our guest this week is Phil Mikins. Phil has been dedicated to antiaging, preventative, and regenerative medicine for more than 30 years. He helps spread the latest international lifespan information to the public by being editor to the Aging Matters magazine. Plus he assists with many other publications and conferences. He also established the IAS group, which is an organization dedicated to finding hard to obtain supplements and health products, some of which we discuss today. In this episode, you’ll learn why so much of the world’s health information is not indexed and easily accessible via PubMed. And worst of all, a lot of what we used to know has been forgotten. If you have interest in either aging, the visual system, the auditory system, or skin, this episode will be jam packed with information. If you want to find the previous episode phil and I recorded together, that will be@mindbodypeak.com the number 10, six, and then this one will be@mindbodypeak.com one, two, three. That’s where you’ll find all the resources and things we discuss if you want to check them out for yourself. And speaking of, if you want to go ahead and grab yourself some of the peptide bioregulators, I would suggest going back to that previous show. And if you use the code Urban in the profound health shop, that’ll save you on your order.

Nick Urban [00:02:07]:

Okay.

Nick Urban [00:02:08]:

Ladies and gentlemen, Phil Micens.

Nick Urban [00:02:12]:

Phil Micens, welcome back to Mind body peak performance.

Phil Micans [00:02:16]:

Thanks, Nick. Great pleasure to be here again.

Nick Urban [00:02:19]:

Yeah, we recorded an episode together. I think it was number 106 and that was a big hit. We talked about peptide bioregulators. We will reference that again in this show. But there are a lot of things we’ve discussed, just you and I offline when the cameras were not rolling and a lot of really cool stuff that I’m going to guess most people have never heard of. And will you share how that is possible, that there’s such cool things out there, such cool inventions and medical health interventions? How can these work if no one’s heard of them?

Phil Micans [00:02:58]:

Right? Well, the bottom line is some people have heard of them, some countries have approved them. But if you talk about mass knowledge, like the world knows Viagra or Prozac or something like that, no, they’re nowhere near that level. And we can certainly get into some.

Phil Micans [00:03:21]:

Of the reasons why.

Phil Micans [00:03:23]:

In fact, I think all the things I want to mention today are effectively natural agents, and that’s one of the major stumbling blocks to getting anything promoted. And unfortunately, whether we like it or not, with the systems that are practiced in the western countries like yours and mine.

Phil Micans [00:03:46]:

They need that promotion.

Phil Micans [00:03:48]:

There are not many doctors, practicing doctors, medical doctors, what we call GPS in the UK, general practitioner who have enough time to look up the research and all the rest. Let’s be honest, most of them might go along to a few medical conferences sponsored probably by pharmaceutical companies, and then wait for the pharmaceutical reps to come in and tell them what’s new. So how can we put it that makes the world rather tainted and rather slanted into one direction. Meanwhile, there can be the most wonderful research that’s been done in different places, some of it being decades old, many decades old. And when you hear about what it works, how it works, and you’d be flabbergasted in some cases, in the medical journals it’s appeared in, right, serious ones.

Phil Micans [00:04:41]:

Or indeed the number of patients who’ve.

Phil Micans [00:04:44]:

Actually used it and it’s been recorded. So on that basis you’d think, oh, why aren’t they using them? But there are all kinds of commercial pressures which we can get into.

Nick Urban [00:04:55]:

Are there any in particular that you like to start out with?

Phil Micans [00:04:58]:

Sure, absolutely.

Phil Micans [00:05:00]:

From one perspective, I’m looking at this, they reckon that presently online, and I’m.

Phil Micans [00:05:06]:

Just talking medicine here.

Phil Micans [00:05:07]:

I’m not talking general health, general nutrition.

Phil Micans [00:05:10]:

Or clinical and personal experiences, of which there’d be far, far more.

Phil Micans [00:05:15]:

But in the medical literature, it’s estimated that today, 50 million publications, 50 million articles are online, 1 million are added every year.

Phil Micans [00:05:26]:

Okay, that’s the present level, but probably.

Phil Micans [00:05:30]:

Somewhere between 15 and 20% is online.

Phil Micans [00:05:34]:

The rest is in the libraries of the world. And of course, that could also mean it’s different languages. It’s not all going to be English.

Phil Micans [00:05:42]:

Could be Chinese, could be Russian, who knows any number of languages. So if we start thinking about an.

Phil Micans [00:05:51]:

Individual or even a group of individuals.

Phil Micans [00:05:54]:

Who are going to go off and.

Phil Micans [00:05:56]:

Find this plethora of information, it soon.

Phil Micans [00:06:00]:

Becomes apparent that with trying to go.

Phil Micans [00:06:03]:

Through the libraries of the world, even.

Phil Micans [00:06:05]:

Trying to do what’s online, and then having a knowledge of what might be.

Phil Micans [00:06:09]:

20 different languages or more is impossible.

Phil Micans [00:06:13]:

There’s no group of individuals who can do it.

Phil Micans [00:06:16]:

So suddenly you can say, well, if.

Phil Micans [00:06:17]:

We had AI, and if it was able to go and read everything that’s already been published and then come back.

Phil Micans [00:06:24]:

To us with a so you type in your problem. So say you type in prostrate cancer just as a sample.

Phil Micans [00:06:32]:

If AI could go away and read.

Phil Micans [00:06:34]:

All that massive literature and come back.

Phil Micans [00:06:36]:

And say, well, I found this, this and this, that could best suit your.

Phil Micans [00:06:40]:

Needs, suddenly you could have the most amazing focus.

Phil Micans [00:06:45]:

And to use a line that I’m rather proud of because I’m writing an article on this, imagine if we did that, we’d actually learn what we’ve already discovered.

Phil Micans [00:06:58]:

Okay?

Phil Micans [00:06:59]:

And that, I think, is a big.

Phil Micans [00:07:00]:

Problem because it’s fantastic that new research.

Phil Micans [00:07:04]:

Is going on and looking for things. But on several occasions in my life.

Phil Micans [00:07:08]:

I’ve heard researchers, quite well known people.

Phil Micans [00:07:12]:

Actually say, we’re looking for this and we’re looking for that.

Phil Micans [00:07:15]:

And I’ll say, oh, it’s already been done.

Phil Micans [00:07:18]:

Haven’t you seen this?

Phil Micans [00:07:19]:

Haven’t you seen that? And they’re always a bit gobsmacked.

Phil Micans [00:07:24]:

There is one example I can give here, which is a bit because what today is about either saying wow or being shocked. A man I have great respect for.

Phil Micans [00:07:33]:

Dr. Jonathan Wright, he runs a clinic in Tahoma in Washington, very big clinic.

Phil Micans [00:07:38]:

Has lots of people underneath him. He actually found a combination of things.

Phil Micans [00:07:43]:

Which I’ll also come to separately, that reverse macular degeneration in people’s eyes.

Phil Micans [00:07:50]:

And it’s a combination of basically minerals and melatonin as well. At one point, and I’m going back.

Phil Micans [00:07:57]:

Quite a few years here, probably even a decade, maybe more now he actually advertised.

Phil Micans [00:08:05]:

Come to my clinic and I.

Phil Micans [00:08:06]:

Will reverse your wet or dry and I’ll get into why that’s important macular degeneration or I’ll give you your money back. Now, that’s not a phrase you hear a lot in doctors’offices and clinics, is it?

Phil Micans [00:08:23]:

And you can imagine the interest.

Phil Micans [00:08:26]:

But the FDA prevented it.

Phil Micans [00:08:28]:

They went to him and they said.

Phil Micans [00:08:29]:

You can’t do this, you cannot give a money back guarantee.

Phil Micans [00:08:34]:

And he said, Why? And they told him it was unfair.

Phil Micans [00:08:39]:

To the doctors who couldn’t.

Phil Micans [00:08:41]:

So I’m not making this up, folks. So can you imagine, can you imagine any other industry where something like that could take place? And then you say, this is your health. This is not getting quite the right.

Phil Micans [00:08:55]:

Tire on your car. Right.

Phil Micans [00:08:57]:

Well, I really wanted the Michelin.

Phil Micans [00:08:59]:

They only gave me the Dunlop. This is not quite like that, is it? I would say it’s a bit more important, yeah.

Nick Urban [00:09:06]:

When I was writing a simple article on the basics of peptide bioregulators, I read two books on it. I looked through PubMed, I looked through other sites that had research, and a lot of it was in Russian. Then I discovered there was an argument over whether or not they translated the dosages properly when they were translating the language. And there’s so many different areas where someone who doesn’t understand all of the nuances of it, like pretty much everyone out there, because there’s so much and it’s not all in native language and the information is scattered, it’s so difficult to get like a simple concise answer. So this is somewhere that AI could really help and there wouldn’t be as much stuff lost in translation and it would all be in one central place rather than 100 different areas around the internet.

Phil Micans [00:09:53]:

And as you correctly say, there are nuances within languages that don’t translate well into our native languages. And just from an English perspective, trying to teach a foreigner the difference between could, would, should. For example, the word nootropics, which I think a lot of people are aware of, which generally speaking means towards the mind, if you like, direct translations. But my good friend Marius, Marius Croazis, who’s a doctor and has written various.

Phil Micans [00:10:24]:

Books, including perhaps one of the peptide.

Phil Micans [00:10:26]:

Books that you read, he was saying it’s like saying the tree and the.

Phil Micans [00:10:33]:

Woods at the same time.

Phil Micans [00:10:35]:

So it’s very difficult to translate into.

Phil Micans [00:10:38]:

English but obviously makes sense in Greek.

Nick Urban [00:10:40]:

Yeah. And to learn more about our episode on peptide bioregulators, how those work, what makes them so special, you can check out the show notes@mindbodypeak.com 106, which was the number of the episode. There was a lot there a lot of questions and a lot of promise behind those. Can you give a quick summary of what peptide bioregulators are?

Phil Micans [00:11:02]:

Indeed, Nick, and I would say this is one of the wow factors. The Soviets, because it was in that.

Phil Micans [00:11:09]:

Time discovered that short chain peptides.

Phil Micans [00:11:13]:

So what do I mean by that? These are very small links of amino acids. A peptide is made up of amino acids and a bioregulator, which is a term that’s been given by Professor Vladimir Cabinson, who’s the lead researcher behind all of this. And they are basically peptides made up.

Phil Micans [00:11:33]:

Of two, three or four amino acids.

Phil Micans [00:11:35]:

So they’re particularly small, but they’re not all bioregulators.

Phil Micans [00:11:40]:

So what they discovered was that these.

Phil Micans [00:11:43]:

And they discovered well, commercially available today there are 21. Although actually if you look at the.

Phil Micans [00:11:49]:

Literature, it was probably approaching 50 that.

Phil Micans [00:11:53]:

They discovered in the literature are in different foods and they are gene switches. So if you stop and think about that for a moment, it’s a hidden message within food. Everybody knows you are what you eat. Everybody knows that expression. Everybody is getting into epigenetics, how food changes us.

Phil Micans [00:12:16]:

And biohacking of course is a big part of that.

Phil Micans [00:12:20]:

Imagine if you knew which peptides, which food groups to silence or activate a.

Phil Micans [00:12:27]:

Specific gene for a specific purpose.

Phil Micans [00:12:31]:

Okay? And you’re really getting into what’s called.

Phil Micans [00:12:34]:

Precision medicine, very much precision medicine.

Phil Micans [00:12:38]:

And the Russians and the Soviets, originally it was a Soviet military secret. They reserved it for their troops, their.

Phil Micans [00:12:46]:

Cosmonauts and their Olympic teams.

Phil Micans [00:12:49]:

But since Perestroika, this stuff has been in the open and today the oral versions, and they work orally. Anybody that knows about peptides knows that most of them don’t work well orally because their chains are too long. But these ones work orally and with all the evidence, all the backup, their food supplements in the Russian countries, it’s not just know, it is Ukraine and Kazakhstan and Georgia and Azerbaijan and other.

Phil Micans [00:13:19]:

Countries in that region.

Phil Micans [00:13:21]:

So they’re sold as food supplements.

Phil Micans [00:13:24]:

They’re incredibly safe.

Phil Micans [00:13:27]:

There are various it’s a long list, 21, but you’ve got things like heart and liver and kidney and pineal and testes and ovaries. There’s a lot there that people, if they’re interested, go to our last time we spoke and look that up. So the implications of them are enormous.

Nick Urban [00:13:48]:

Yeah. And what really stands out about them to me is they work epigenetically. So they don’t actually change your genes, but they change the expression of your genes. They’re also very safe. They’re orally bioavailable, and they’re naturally contained in small quantities within food. So it’s like we’re already consuming these, but not enough to have the same the full therapeutic benefit that you want if you’re, say, targeting your liver or your heart or your kidneys or your reproductive system.

Phil Micans [00:14:14]:

That’s absolutely right. And the incredible thing that most people can’t get their heads around and I don’t think actually, the science has been completely resolved on this is the word bioregulator, because what the same peptide can.

Phil Micans [00:14:29]:

Do with that specific gene is activate it or silence it. So, for example, let’s take the thyroid gland in the neck.

Phil Micans [00:14:39]:

A lot of people, they have a weak thyroid. They’re not producing enough thyroid hormones or to adults, and they’re hypothyroid.

Phil Micans [00:14:48]:

There’s too little. If you take the thyroid peptide, it will actually, through the gene, encourage the thyroid. You do need the thyroid, of course. Persons who’ve had it removed don’t work, right? Don’t do nothing. But let’s say you have got the thyroid.

Phil Micans [00:15:04]:

It will activate them to make more thyroid hormones. So this is really fundamental. It’s endogenous.

Phil Micans [00:15:12]:

In other words, it’s happening inside the body. It’s not you taking a thyroid hormone, which would be exogenous outside the body. But here’s the crazy thing. If you were one of the rarer persons who is producing too much thyroid hormones, I e. Your hyperthyroid, it will silence the gene, and you’ll stop manufacturing as much thyroid hormones.

Phil Micans [00:15:37]:

And it bioregulates.

Phil Micans [00:15:39]:

Think of it like an adaptogen.

Phil Micans [00:15:41]:

I think a lot of people are familiar with that term these days.

Phil Micans [00:15:45]:

So it’s like an adaptogen.

Phil Micans [00:15:46]:

And it may also help to explain why in Russia, and Professor Cabinson has spoken of this openly, saying it’s been dosed over 100 million times in millions of people.

Phil Micans [00:16:02]:

Because remember, folks, this has been happening over 40 years. This wasn’t discovered last week. They haven’t seen any serious side effects. And it could help to explain that you don’t appear to be able to overdose.

Nick Urban [00:16:18]:

And I think that normal peptides tend to be among the safer class of therapeutics. But then bioregulators are even a notch above that.

Phil Micans [00:16:28]:

There’s a lot of peptides out there. Hell of a lot. I mean, when you think about it, you got your amino acids, and then, of course, depending on where they are in the chain and how long the chain is, you start going up, you start calling them. There are all sorts of I did look up the other day, the longest peptide, I think it was around 50 amino acids. It’s quite long. But we start calling them proteins.

Phil Micans [00:16:51]:

We even start calling them hormones, right?

Phil Micans [00:16:53]:

So take another example. Human growth hormone, if memory serves me correctly, is 191 amino acids. So hell of a long one, you’d never be able to swallow it, it.

Phil Micans [00:17:06]:

Wouldn’T work, it would never get through the stomach.

Phil Micans [00:17:08]:

That’s why it has to be injected.

Nick Urban [00:17:10]:

And I think a natural source of some of these bioregulators, again in much.

Nick Urban [00:17:14]:

Smaller doses than if you took a.

Nick Urban [00:17:16]:

Dedicated supplement, would be in the respective organ. So say if I ate liver then I’d be getting a small dose of the liver bioregulators in some form.

Phil Micans [00:17:25]:

Absolutely. It goes back even to the work.

Phil Micans [00:17:30]:

Of people like Weston Price, who if.

Phil Micans [00:17:33]:

I remember rightly, you’re talking like twenty s, thirty s, forty s who made discoveries in native tribes around the world.

Phil Micans [00:17:40]:

Some of which aren’t there anymore.

Phil Micans [00:17:44]:

And saying that I remember one in.

Phil Micans [00:17:46]:

Particular, if memory serves me right, it.

Phil Micans [00:17:48]:

Was a Hunza tribe in Pakistan.

Phil Micans [00:17:50]:

I might be wrong, but I think it was.

Phil Micans [00:17:53]:

And they ate the necks of the animals.

Phil Micans [00:17:55]:

In fact our forebears would have wasted.

Phil Micans [00:17:59]:

Know, maybe mum or Know made chicken.

Phil Micans [00:18:02]:

Soup from the bones.

Phil Micans [00:18:04]:

You’d had the meat and of course it wasn’t that long ago when people.

Phil Micans [00:18:08]:

Ate the organ meats.

Phil Micans [00:18:10]:

And now we’re so fussy. We don’t want the black meat of.

Phil Micans [00:18:13]:

A chicken, we only want the white.

Phil Micans [00:18:15]:

Meat and then we only want the.

Phil Micans [00:18:16]:

Breast maybe, I don’t know.

Phil Micans [00:18:18]:

But in days not so long ago the entire animal was consumed.

Phil Micans [00:18:23]:

And Weston Price in his studies showed that the tribes who are eating, in.

Phil Micans [00:18:28]:

This case the necks of animals, didn’t.

Phil Micans [00:18:31]:

Have any thyroid problems.

Phil Micans [00:18:32]:

And it could well be the peptides in those meats through gene switches that is responsible.

Phil Micans [00:18:42]:

Just as a side note, one of.

Phil Micans [00:18:44]:

The most respected thyroid medications is what’s.

Phil Micans [00:18:48]:

Called desiccated thyroid which comes from a pig.

Phil Micans [00:18:51]:

So when you consume a pig poor sign to give it the right name, thyroid, you’re getting a cross reference to those, you might be getting the right balance. And I always thought that when I.

Phil Micans [00:19:02]:

Heard patients say oh, I’m doing so.

Phil Micans [00:19:04]:

Much better now that I’m using these.

Phil Micans [00:19:07]:

Natural thyroids, I always thought that was the only reason.

Phil Micans [00:19:11]:

And a few years ago I discovered.

Phil Micans [00:19:13]:

That the porcine thyroid is bioidentical to human.

Phil Micans [00:19:18]:

That doesn’t happen very often in the.

Phil Micans [00:19:20]:

Animal world, but it is. So there’s a double whammy.

Phil Micans [00:19:24]:

So that really explains it. But I think now with this new information the world’s moved on the next step, which is in understanding the foods, the peptides and the genes.

Nick Urban [00:19:36]:

Well, let’s talk more about the visual system now because you briefly mentioned to me about some of these cool products and the information behind them, but I’m still mostly in the dark around these. So I’m interested to hear what they are, how they work and if there is any research or anecdotes that you’ve heard about each of them.

Phil Micans [00:19:56]:

So I guess stick to the visual.

Phil Micans [00:19:59]:

I’ve got two visuals to talk about today. I’ll mention the one first that I’ve already alluded to, which is for macular degeneration and in case folks don’t know, macular degeneration is basically a breakdown on.

Phil Micans [00:20:18]:

The retina in the eye, the back of the eye.

Phil Micans [00:20:20]:

And there are two forms. One is called dry, which is much more prevalent. Probably 80% of the people, maybe more, who have macular generation are dry. And generally it starts dry, which kind.

Phil Micans [00:20:33]:

Of means it’s not bleeding, literally, it’s.

Phil Micans [00:20:36]:

Dry and then you get wet. Where is a bigger problem.

Phil Micans [00:20:43]:

And the situation in most countries is.

Phil Micans [00:20:47]:

So bad that if you go along to the dock and what happens is literally part of your vision will evaporate. If you put a pencil in front of your eye, can you imagine? Have you moved around that that bit.

Phil Micans [00:21:02]:

You couldn’t see and it couldn’t get worse?

Phil Micans [00:21:05]:

It depends where on the retina, it.

Phil Micans [00:21:07]:

Depends on the size, but generally it gets worse until eventually you might not see anything at all.

Phil Micans [00:21:13]:

So it’s extremely concerning. Obviously, generally, most people, it starts off.

Phil Micans [00:21:19]:

Dry and it can be dry for quite a long time. The drugs that are available are so expensive, so difficult to administer, they are.

Phil Micans [00:21:31]:

Injected into the eyeball and that can be done, like every two or three months. And so expensive. Now, the last time I looked them up was a few years ago, but I’m just talking about the cost of the drug now. I’m not talking about the doctor’s time.

Phil Micans [00:21:49]:

The clinic and the insurance, the equipment and all the rest of it was.

Phil Micans [00:21:53]:

Running over $1,000 per injection.

Nick Urban [00:21:56]:

Wow.

Phil Micans [00:21:56]:

And the clinical studies are showing that.

Phil Micans [00:21:59]:

After two years of doing this, every one, two, three months, it’s 50 50, whether it makes an improvement. An improvement. Right.

Phil Micans [00:22:12]:

So, in other words, it’s not particularly stunning, it’s expensive. I don’t think anybody wants to see.

Phil Micans [00:22:20]:

Something coming towards their eye, et cetera, et cetera.

Phil Micans [00:22:24]:

So wouldn’t it be nice to find something that is more effective? Well, going back to Jonathan Wright, he found literature going way back about injecting minerals.

Phil Micans [00:22:36]:

But what I was wanting to focus on was a study that was published in 2005 in the New York Academy of Sciences respected journal that was conducted in China. There were 100 patients, there were 110 eyes because some patients had a problem in both of their eyes. Right.

Phil Micans [00:22:59]:

And they were suffering from wet and dry. So I should have mentioned that many countries around the world, including my own, if I went along to my NHS hospital and they said, you’ve got dry.

Phil Micans [00:23:11]:

Macular degeneration because of the cost and because of the paucity of effects, they.

Phil Micans [00:23:18]:

Will normally say, we’re not going to treat you now, come back when it’s wet. So, in other words, when it’s got.

Phil Micans [00:23:24]:

Really bad, we’ll do something about it.

Phil Micans [00:23:27]:

So in this study in China, like.

Phil Micans [00:23:30]:

I say, 100 patients, 110 eyes, some had dry, some had wet.

Phil Micans [00:23:35]:

I can’t remember the exact breakdown of the numbers between the two at the.

Phil Micans [00:23:38]:

Moment, but what they gave everybody was very simple. They gave them, every night, three milligrams of melatonin, 50 milligrams of zinc, and if memory serves me correctly, 50 micrograms of selenium.

Nick Urban [00:24:00]:

Is this oral?

Phil Micans [00:24:02]:

Yeah, it was actually all put into one pill. So they gave these folks that every night.

Phil Micans [00:24:08]:

Okay. Nothing else? Didn’t do anything else.

Phil Micans [00:24:12]:

What they found was and what they took were called fungus pictures, which is.

Phil Micans [00:24:16]:

Kind of pictures from the back of the eye. Within three months, there were already significant improvements in both wet and dry.

Phil Micans [00:24:27]:

And there are countless in the article, you’ll see countless before, during, after.

Phil Micans [00:24:32]:

Okay. They did it for six months. At the end of six months.

Phil Micans [00:24:39]:

99% of the people no longer had wet.

Phil Micans [00:24:45]:

Or dry macro degeneration.

Phil Micans [00:24:46]:

The other 10% had made improvements, but.

Phil Micans [00:24:49]:

Perhaps hadn’t eradicated it. What side effects were there? All dreadful side effects.

Phil Micans [00:24:55]:

People had better sleep, more energy, and felt less depressed. And we did a cost analysis on it at the time. Bear in mind, it’s going back a.

Phil Micans [00:25:03]:

While now, back to around 2005, 2007. I think we were aware of this.

Phil Micans [00:25:10]:

And we were working out that if.

Phil Micans [00:25:12]:

You’D have had standard treatment, the cost.

Phil Micans [00:25:16]:

Of the therapy would be running at sort of anywhere between 1520, $25,000.

Phil Micans [00:25:23]:

Okay.

Phil Micans [00:25:24]:

And we worked out that the cost.

Phil Micans [00:25:26]:

Of this treatment, making some allowances for the health professionals, time to check on you and what have you, but you hardly need to be monitored. You still go home.

Phil Micans [00:25:40]:

Could be running as much as $100 a year. And so I put that down as.

Phil Micans [00:25:45]:

One of the wow factors.

Nick Urban [00:25:47]:

Would you stick with that long term after the six months, or would you do it and then stop?

Phil Micans [00:25:53]:

I see no reason not to. In fact, there is a strong argument for us older people, because if we.

Phil Micans [00:25:59]:

Start now talking about antiaging, or shall we call it preventative medicine, I’m a strong advocate for melatonin, and I see no reason why. And I think there are many other.

Phil Micans [00:26:11]:

Minerals that people are. Deep magnesium, for example, is a big problem.

Phil Micans [00:26:18]:

So, yeah, good stuff.

Phil Micans [00:26:20]:

Selenium, good stuff.

Nick Urban [00:26:22]:

Melatonin is not very misunderstood. There are some people who experience, like, a paradoxical melatonin effect where after three or 5 hours, they wake up wide awake, and it doesn’t work the way it does for most people, perhaps. I wonder if it would work as well for them. And I don’t know if liposomal melatonin or extended release melatonin would work better for them.

Phil Micans [00:26:44]:

You’ve hit the nail right on the head. This is where we get into what used to be called chrono geriatrics, which.

Phil Micans [00:26:53]:

Is the timing of things.

Phil Micans [00:26:54]:

And again, coming back to my favorite doctor, Jonathan Wright, he always says if things are going wrong and we’re not copying nature, we’re either using the wrong.

Phil Micans [00:27:05]:

Molecule, the wrong dose, or the wrong timing. And of all the things today in.

Phil Micans [00:27:12]:

The world of preventative antiaging medicine, timing is probably the least well known and.

Phil Micans [00:27:20]:

The least well addressed. One example, we are not fans of Pellets hormone Pellets. If a man has a testosterone Pellet.

Phil Micans [00:27:29]:

Inserted into his backside, all this is so convenient. I only have to go in every three months, and the doctor puts another.

Phil Micans [00:27:38]:

One in and blah, blah, blah.

Phil Micans [00:27:40]:

But imagine the release of that testosterone. We don’t have AI.

Phil Micans [00:27:45]:

Nano driven pellets. We might do one day, but we.

Phil Micans [00:27:49]:

Don’T at the moment. So what you end up getting is this constant release of Melatonin into your system.

Phil Micans [00:27:56]:

That’s not natural.

Phil Micans [00:27:58]:

If you did a chart of time and the amount of testosterone in blood time on this axis, and Aldosterone, you’d see it be quite big in the morning, a big pulse site release, and maybe a few smaller pulsite releases as the day goes on. And if we do some exercise, it.

Phil Micans [00:28:17]:

Would have another one, but it’s not doing that, right. So you’ve got to ask yourself, what does that do? What damage can occur? So, coming back to melatonin, one of.

Phil Micans [00:28:28]:

The great things that Walter and his team did was they looked at the natural pulsite release of Melatonin.

Phil Micans [00:28:36]:

Now, melatonin is very unique because it’s not in us in daylight, but it.

Phil Micans [00:28:43]:

Comes out in us when we go into darkness.

Phil Micans [00:28:46]:

Which does mean if you go to the cinema at 02:00 in the afternoon.

Phil Micans [00:28:50]:

Or you get on that flight and they pull down the shades and it’s.

Phil Micans [00:28:54]:

Still 02:00 in the afternoon, but suddenly.

Phil Micans [00:28:56]:

You feel tired, it’s the reaction of melatonin, because what’s it there for? It’s there to tell the body, it’s nighttime, you should be sleeping. And the reason for that is it sends signal. Walter once described the pineal gland to me, which is the primary source of Melatonin.

Phil Micans [00:29:13]:

He once said to me, consider it.

Phil Micans [00:29:15]:

The conductor of the endocrine system.

Phil Micans [00:29:17]:

If you have a conductor of an orchestra, what happens? You make music. But if you have an orchestra without a conductor, what happens? It makes noise.

Phil Micans [00:29:25]:

So Melatonin by dissipating during daylight is.

Phil Micans [00:29:29]:

A signal to the hormones.

Phil Micans [00:29:31]:

And that’s why most hormone, big hormone, are in the morning, your growth hormone, your testosterone, because it’s an impetus to.

Phil Micans [00:29:38]:

Get up and get on with the day, right?

Phil Micans [00:29:41]:

And that is a result of Melatonin leaving the blood.

Phil Micans [00:29:45]:

There are many other aspects to Melatonin. So if your circadian rhythms are correct, your day night cycle, right?

Phil Micans [00:29:53]:

Once you’ve got that correct, your hormonal.

Phil Micans [00:29:56]:

Cyclicity will be correct.

Phil Micans [00:29:58]:

And when your hormonal cyclicity is correct.

Phil Micans [00:30:00]:

Your immune system will be strong. So all these things go hand in glove. But what Walter and his team realized.

Phil Micans [00:30:10]:

Is the natural night peak of Melatonin.

Phil Micans [00:30:14]:

Is between 01:00 A.m. And 03:00 A.m..

Phil Micans [00:30:16]:

That’s probably why it’s there.

Phil Micans [00:30:18]:

The most important hours to be asleep, right? A lot of REM activity takes place at the same time, rapid eye movement.

Phil Micans [00:30:29]:

So some of the melatonins on the.

Phil Micans [00:30:32]:

Market, they are time released but how?

Phil Micans [00:30:36]:

Do you want a long slow release that may still be with you at 06:00 A.m.

Phil Micans [00:30:40]:

In the morning? Or do you want a sublingual tablet which is going to go and be out of you in half an hour?

Phil Micans [00:30:47]:

Neither may not be unless you’re going.

Phil Micans [00:30:49]:

To get up at 01:00 in the morning and suck on that sublingual and then go back. It’s cost and convenience. Walters MZS, what it is or what it does, I should say, is he says you must take it between 09:00 and 11:00 at night. You do not saves to go to bed.

Phil Micans [00:31:07]:

It is not necessary to go to.

Phil Micans [00:31:09]:

Bed, a lot of people say, but light entering the eye destroys melatonin. That’s true, that’s absolutely true. But it only destroys endogenously produced, in.

Phil Micans [00:31:20]:

Other words, naturally produced melatonin.

Phil Micans [00:31:22]:

If you’ve just thrown a tablet into your stomach, it will not stop that at all. Okay?

Phil Micans [00:31:29]:

So by taking MZS between 09:00 p.m. And 11:00 p.m., you are putting that melatonin into your blood between 01:00 A.m. And 03:00 A.m.. So you’re absolutely right.

Phil Micans [00:31:41]:

Timing can also be a very important factor.

Nick Urban [00:31:46]:

Okay. And then the other question I had with that is the decision to only include a couple of minerals, zinc and selenium. What about copper to balance the zinc to copper ratio?

Phil Micans [00:31:59]:

There are many other things you can.

Phil Micans [00:32:02]:

Get into, but on a simplistic level.

Phil Micans [00:32:04]:

I mean, Jonathan Wright used to give.

Phil Micans [00:32:06]:

A multitude of different minerals by injection.

Phil Micans [00:32:10]:

I hastened to add, but he found.

Phil Micans [00:32:12]:

That the patients who were already suffering.

Phil Micans [00:32:15]:

With macular degeneration were in the bottom quartile. If up here is absolutely premium optimal in terms of your mineral balance, most of us are operating in the middle suboptimal, but the folks who’ve got the problems, they’re right down the bottom, right. So he found in many cases, maybe not in all cases, many cases they needed that boost. That could only be provided by injections.

Phil Micans [00:32:42]:

In his particular case.

Phil Micans [00:32:44]:

But I think that’s a big tick. If we can really successfully treat macular degeneration in a large percentage of people I’m never going to say it’s 100%, there’s all sorts of complications, but imagine that. Imagine that. And really for very little money. It’s a win win, absolute win win. If we stay in the visual field.

Phil Micans [00:33:10]:

There’s another big one.

Phil Micans [00:33:13]:

And really weirdly, okay, what we talked about was Italian and Chinese research, but this is going.

Phil Micans [00:33:21]:

To be Russian research again.

Phil Micans [00:33:24]:

And it originated in the early, very early 2000s from a place called the.

Phil Micans [00:33:31]:

Helm Holtze Institute in Moscow, who gave the world cataract surgery all those years ago. And they back then again 90s looked.

Phil Micans [00:33:43]:

At the way the world is population.

Phil Micans [00:33:46]:

Is going lots more older people because cataract, or to be specific, senile cataract is predominantly a problem of people in their fifty s and up. There are different kinds of cataract. You can get cataract by an accident in the eye. But senile. Cataract, the most prevalent one, is generally associated with age. They realized back in the 90s that.

Phil Micans [00:34:13]:

With the world getting older, as we.

Phil Micans [00:34:15]:

All know, although cataract surgery is very effective and also is the safest form of surgery known because you know how many cataract surgeries take place every day around the world. However, in 2% of cases, there are complications. And you don’t want to be one of those 2%, do you? No. Okay. Surgery, very nature of it.

Phil Micans [00:34:38]:

It has an inherent risk, obviously, but.

Phil Micans [00:34:42]:

The Russians said, okay, that aside, we’re not going to have enough trained surgeons by 2050 or whatever to deal with the numbers of people.

Phil Micans [00:34:52]:

So they were given a job to.

Phil Micans [00:34:55]:

Go and find something that would help.

Phil Micans [00:34:58]:

And the bottom line was, they found.

Phil Micans [00:35:00]:

That another dipeptide, two amino acids called carnosine, seems to be a natural protectant within the eye. Specifically, it is an antiglycation agent. A lot of people think it’s an antioxidant or a free radical scavenger, maybe, but we think its predominant protective role is antiglycation, which is to prevent proteins, sugars and oxygen from cross linking, which impairs the proteins. So what happens?

Phil Micans [00:35:37]:

You imagine the lens is in the middle of your eye and it’s surrounded.

Phil Micans [00:35:41]:

By this liquid, which is called the aqueous humor. So the light comes through the eye.

Phil Micans [00:35:47]:

Hits the lens, and then the lens changes its shape by the muscles.

Phil Micans [00:35:52]:

Bit like a telescope. Right. You change a lens to look in the distance. What happens in the eye? Same thing. And then, of course, it puts the light onto the retina for you and then from there to the brain. But with glycated, the crystallines within the lens, they become impaired and they become clouded, and they can go from white to yellow to even brown. So the main product, the original product, was called Can C. Obviously, it’s quite a good name. And it’s two drops twice a day.

Phil Micans [00:36:25]:

And gets in there. And the human clinical studies, and there’s been three today.

Phil Micans [00:36:31]:

Not huge, I admit.

Phil Micans [00:36:33]:

The biggest one was 48 people, but have shown that if used over five.

Phil Micans [00:36:38]:

To six months, 89% of the people will improve their eyesight.

Phil Micans [00:36:46]:

And there have been cases where there.

Phil Micans [00:36:48]:

Have been a complete eradication of cataract. There’s a bit more to cancer, but I don’t like to go down this road because I can’t point you to any hard clinical evidence, but I can.

Phil Micans [00:37:02]:

Tell you about doctors who use it.

Phil Micans [00:37:04]:

And have given statements to this effect and, of course, patients. But it can lower intraocular pressure of the eye. Not big time, but it can. And we think we know why.

Phil Micans [00:37:18]:

So what happens is these Glycated proteins.

Phil Micans [00:37:24]:

They exist in other parts of the eye. There are two places of significance. One is called the schlem canal, and it’s literally the valve that kind of puts things back into the blood screen. The theory is that these Glycated proteins can also block the schlem canal. Think of it as a clogged drain or a part clogged drain.

Phil Micans [00:37:51]:

So what? Who cares?

Phil Micans [00:37:53]:

Big deal. Well, that can lead to the pressure of the eye building up because the wastes are not being removed properly could be part of glucoma. Imagine. Now, we’ve seen patients who have reduced that pressure, and it’s theorized that the action of carnosine in helping to break up and prevent Glycated proteins from occurring in the first place will actually unclog the drain. More dramatically than that are people who suffer with dry eyes. Now, dry eyes is literally where the tears because we think, well, I’m not crying. Are you talking tears?

Phil Micans [00:38:36]:

They’re happening all the time.

Phil Micans [00:38:37]:

The eye is putting a fluid on itself all the time. Otherwise, every time you blinked, you go, Ow, ow, ow. And that is, in extreme cases, what happens to people with very bad dry eyes. Well, you got lacrimal ducts. We think the same thing’s happening. They get blocked by these Glycated proteins. So when they’re reduced and removed, more fluid comes back on the eye. Now, there are two lubricants in canc in order to aid the comfort of the product. Okay? And originally, when I heard this many.

Phil Micans [00:39:10]:

Years ago, people coming back to me.

Phil Micans [00:39:12]:

And saying, wow, it’s really good for dry eyes, isn’t it? And I go, well, yeah, it’s got lubricants in, isn’t it? I mean, there’s 1000 products on the market with lubricants in. And then they go, no, I don’t use it anymore. What? No, I’ve used it for six months. I don’t have dry eyes anymore. I don’t use it anymore.

Nick Urban [00:39:34]:

Yeah. And so the way can see works is it helps prevent glycation, which, to summarize, when you spike your blood sugar, for example, you cause a lot of downstream issues, like the stickiness, so to speak, of the sugar wreaks havoc around the body and especially in the eyes. That’s like one of the main sites where it causes damage. And you can actually see this yourself. If you go out and you eat, like a really sugary meal and you try and do something later, that requires very precise vision in sight. You can actually see your vision get worse an hour, 2 hours after a high sugar meal compared to earlier in the day when you haven’t eaten.

Phil Micans [00:40:11]:

Absolutely. Nick and of course, it’s a problem for diabetics because one of the measures is to see how many Glycated proteins are in a person and say, oh, you’re diabetic. I mean, you can measure the blood glucose as well, of course, but aba.

Phil Micans [00:40:29]:

One C and other factors, how many Glycated proteins are circulating in that person? And as you rightly said, if you.

Phil Micans [00:40:36]:

Don’T know you’ve got diabetes, you may go along to your doc when you.

Phil Micans [00:40:40]:

Start saying, my vision is blurry, right, or My urine is sticky, or there’s 100 different ways of doing it.

Phil Micans [00:40:49]:

But absolutely right. People who eat a lot of sugar might suddenly find their eyesights deteriorated.

Nick Urban [00:40:55]:

But so if my vision was a little blurry for no particular reason, like I don’t have cataracts, I don’t have AMD, these wouldn’t necessarily be you didn’t.

Phil Micans [00:41:05]:

Have four pints of beer.

Nick Urban [00:41:07]:

Yeah, that too. None of that. But I guess it’s age related. Perhaps my vision is slowly deteriorating. Or say I already had glasses and my prescription keeps getting worse and worse. These wouldn’t necessarily be my things to look into, would they?

Phil Micans [00:41:24]:

It’s a good question.

Phil Micans [00:41:26]:

If it’s genetic, perhaps not. I was told long ago that in most people, the average person, as we get older, the eyesight will actually lengthen and then come back the other way later on. That’s why if you go into a.

Phil Micans [00:41:47]:

Hotel and you see the old folks.

Phil Micans [00:41:49]:

Reading the newspapers, they’re all holding them out there.

Phil Micans [00:41:52]:

Right.

Phil Micans [00:41:54]:

You would normally hold them here. They’re all holding them out there, but.

Phil Micans [00:41:57]:

They haven’t got their glasses on to do the adjustment.

Phil Micans [00:42:00]:

I don’t know.

Phil Micans [00:42:00]:

I think there’d be it could I’m.

Phil Micans [00:42:03]:

Not saying it wouldn’t, but I’m not.

Phil Micans [00:42:04]:

Saying it would be my first choice.

Nick Urban [00:42:07]:

All right. That’s fairly comprehensive for the visual system. We got two different things to look into there. And then on the auditory side for hearing, I know there’s another wow factor there. Yeah.

Phil Micans [00:42:18]:

Thanks, Nick. Again, this is one from my favorite.

Phil Micans [00:42:22]:

Doc, dr. Jonathan Wright. That’s right. With a W, by the way, if anyone’s looking him up.

Phil Micans [00:42:28]:

1940S research rediscovered by his university students. And what it was is a hormone called aldosterone, and it’s produced in the adrenal glands. And the average average, that’s probably not the right word. The normal use for it is to help with.

Phil Micans [00:42:49]:

Salt balance in the blood.

Phil Micans [00:42:52]:

And even sometimes it has a role in people’s balance. When I look around different countries and.

Phil Micans [00:43:01]:

I travel a reasonable bit, there are.

Phil Micans [00:43:03]:

Too many young people wearing glasses.

Phil Micans [00:43:06]:

It’s got to be a nutritional thing.

Phil Micans [00:43:08]:

I think, amongst other things, possibly. But there’s something going on there that.

Phil Micans [00:43:12]:

I think needs addressing.

Phil Micans [00:43:15]:

So I was going to say, the.

Phil Micans [00:43:16]:

High streets in our countries are full.

Phil Micans [00:43:19]:

Of shops that are selling glasses and hearing AIDS.

Phil Micans [00:43:23]:

It’s treating a symptom.

Phil Micans [00:43:25]:

It’s not getting to the cause. So what did Jonathan Wright and his team discover?

Phil Micans [00:43:31]:

Well, they discovered from 1940s research that patients who were having trouble hearing, who.

Phil Micans [00:43:41]:

Had no physical damage to their ear were given.

Phil Micans [00:43:44]:

Aldosterone, regained their hearing. Now, one interesting side note to point out here, which has been covered by.

Phil Micans [00:43:56]:

A guy called Dr. Rich Lippman.

Phil Micans [00:43:58]:

He thinks there are two hormones that are very predominant in hearing. One is aldosterone for the volume, and the other is IGF one or insulin like growth factor for the detail. Okay. But in most people’s cases, I would suggest it’s the volume that’s the problem. So it turns out that when they gave, they’ve now since then developed a test whereby they can more or less.

Phil Micans [00:44:31]:

Say if your aldosterone levels are here.

Phil Micans [00:44:35]:

Or lower and you have hearing loss, you will probably benefit by taking some aldosterone. Okay?

Phil Micans [00:44:43]:

Because, of course, if your autosterone levels.

Phil Micans [00:44:47]:

Are quite good, it may be something else. However, there is a large group of people who have taken autosterone and got their hearing back. Now, two things to point out here.

Phil Micans [00:45:01]:

That when they gave these patients some autosterone, they were giving them approximately 125 micrograms orally, that within a few days, their hearings returned to a near normal state. Now, did they have to keep taking autosterone? Yeah, maybe not every day, but they were keeping these, monitoring the levels, keeping.

Phil Micans [00:45:24]:

It up since then.

Phil Micans [00:45:28]:

And I’m happy to say I had.

Phil Micans [00:45:30]:

A hand in this. There has been a liquid auto steroid made. It’s called aldo pro, and it’s in drops. Now, originally designed for sublingual use until a bunch of docs say, what if it’s eardrops? What happens is over several hours, the hearing is improved.

Phil Micans [00:45:52]:

Now, you might say, well, what on earth’s going on?

Phil Micans [00:45:54]:

How can you put it in your ear? Well, it turns out it’s a signaling molecule.

Phil Micans [00:46:01]:

So the little hairs, which I’ve forgotten the name for inside our inner ears, are obviously vibrating with the air movements. That’s what tells us.

Phil Micans [00:46:11]:

But it’s the signal from those to.

Phil Micans [00:46:13]:

The hearing center in the brain, and aldosterone appears to be part of that signaling.

Nick Urban [00:46:20]:

Aldosterone has an impact here, and actually applying it works like a signaling molecule, and we get some of the benefits. We actually notice a pretty immediate effect if we’re going to notice one when applied through to the ear. So how would you recommend going about addressing this deficiency, like the insufficient production? Are there things we can do so that we produce more aldosterone on our own?

Phil Micans [00:46:47]:

The one thing I remember, because some.

Phil Micans [00:46:50]:

People hate this stuff personally, I love it was licorice.

Phil Micans [00:46:54]:

He was saying there were ingredients in.

Phil Micans [00:46:56]:

Licorice that were very good, but there.

Phil Micans [00:46:59]:

Were other things in that book.

Phil Micans [00:47:00]:

So there are obviously foodstuffs that will support our adrenal glands. So I would look to that. Coming back to the three, if you will, at the top of the pyramid, where I tend to spend most of my time is I would look at.

Phil Micans [00:47:15]:

Melatonin as a general addresser, but don’t go overnight with it.

Phil Micans [00:47:21]:

Allow three months before you make your mind up. I think it would be worth thinking about the adrenal peptide bioregulators.

Phil Micans [00:47:29]:

Although it’s only popped in my head.

Phil Micans [00:47:31]:

I don’t see why it shouldn’t have an effect in that department.

Phil Micans [00:47:36]:

And of course, there is aldosterone itself.

Nick Urban [00:47:39]:

What’s cool about these, and specifically that last one, is that you can use the drops initially, figure out if that’s what the issue is. You notice that relief, or lack thereof, pretty quickly, and then you can say, okay, I’m going to focus on naturally improving my aldosterone levels now and then. You don’t need the drops. Eventually and you take care of it through peptides bioregulators lifestyle.

Phil Micans [00:48:00]:

You’d only use it on odd occasions. You might say, oh, I really need to hear, know, or whatever, with one caveat there, Nick, and that is make.

Phil Micans [00:48:10]:

Sure your ears are nice and clean first time you use it. This last one I’d like to tell you about. His name is Dr. Bill Cham. When he was a young man, he.

Phil Micans [00:48:19]:

Walked around his island and he noticed.

Phil Micans [00:48:22]:

That horses and cows, etc, would sometimes rub themselves up against this local plant, which they call the devil’s apple, but is actually a relation to eggplant. Okay? And he asked the farmers, because he.

Phil Micans [00:48:37]:

Was a budding biochemist training, and he.

Phil Micans [00:48:43]:

Asked the local farmers, why do the animals do this? And their reply was, well, they get lesions on their skin, and they instinctively, when they get them, rub themselves up against this plant.

Phil Micans [00:48:56]:

And Bill said, weird, does it help?

Phil Micans [00:49:00]:

And the farmer said, well, funny enough, yeah, it does. So this fascinated him, and he spent 20 years researching and what he discovered, he discovered an ingredient within this plant called celestine. Okay. And what those lesions were, by the way, so I should point out they’re known they’re cancer, skin cancer, we’re talking about. They are what’s known as squamous cell carcinomas and basal cell carcinomas. It’s 100% effective in removing basal cell and squamous cell carcinomas. It’s a cream, and you put it on twice a day. 100%. If it was around the eye, inside.

Phil Micans [00:49:50]:

The mouth, perhaps on the anus somewhere.

Phil Micans [00:49:52]:

It’S possibly wet, it’s not going to help you. But the majority of these kind, which are caused mainly by over sun exposure, right.

Phil Micans [00:50:02]:

You know, they can start as what’s.

Phil Micans [00:50:03]:

Known as keratosis, which is called a sunspot, by the way.

Phil Micans [00:50:06]:

It gets rid of those in days.

Phil Micans [00:50:08]:

80,000 patient cases documented. 80,000 patient cases documented. They know exactly how it works. What it does turns out that cancer cells, they coat themselves with rhymose coating that is not present on a health cell.

Phil Micans [00:50:34]:

It removes this rhymose coating. And the moment it removes that rhymose.

Phil Micans [00:50:38]:

Coating, it would appear that the immune system says, ah, you’re a non self cell, and the natural process of apoptosis takes place. The cream is called Beck Five curaderm named after the inventor Bill Edward Cham. That’s why it’s called beck. Okay.

Nick Urban [00:50:56]:

Well, Phil, this has been a blast. We’ve covered a lot of ground, a lot of different therapeutics. Again, last time we mentioned you coming on and talking about nootropics, but that will have to happen at a later date because we could easily talk for a lot longer about each of the different remedies and things that we were discussing today. But so far, if people want to connect with you to follow your work, to subscribe to your magazine, which I’ve been loving, how can they get a hold of you? Yeah.

Phil Micans [00:51:25]:

Thanks, Nick. Yes, thank you. The magazine we have published all these stories I’ve spoken about today, and folks can download them for free, or they can pay us $10 and have one.

Phil Micans [00:51:37]:

Delivered to their door, whatever you like. And that website is called Agingmatters.com. Agingmatters.com.

Phil Micans [00:51:46]:

That’s all laid out there. And if you want even more detail on even more subjects, our main website.

Phil Micans [00:51:54]:

Which has existed since 1996, if memory serves me right, or maybe a bit.

Phil Micans [00:51:58]:

Earlier, so it’s accumulated a lot of.

Phil Micans [00:52:01]:

Pages, is Antiaging systems.com.

Phil Micans [00:52:05]:

So that will give you references, video.

Phil Micans [00:52:08]:

Links, all that sort of thing.

Nick Urban [00:52:10]:

Absolutely. Phil, a couple more rapid fire questions for you before we part ways today. First of all, what unusual substance or nootropic or vitamin or supplement or whatever have you used today or recently?

Phil Micans [00:52:25]:

I’m not going to mention its name just at the moment, but I am.

Phil Micans [00:52:30]:

Just about to start experimenting with a supplement that increases stem cell activity. I’m pretty focused on the work of Bill Falun, who’s the owner of the Life Extension Foundation, and Bill is terrific.

Phil Micans [00:52:51]:

Guy, and he has a couple of.

Phil Micans [00:52:53]:

Organizations other than Life Extension, he has.

Phil Micans [00:52:56]:

The Age Reversal Network, which is well worth if you want to really be serious. And this is going to be the.

Phil Micans [00:53:04]:

Lead story in our next magazine.

Phil Micans [00:53:06]:

He’s got this idea which he calls the Stairstep approach to biological age control.

Phil Micans [00:53:14]:

And each step is a biochemical pathway.

Phil Micans [00:53:18]:

So we’ve got things like mTOR, autophagy, AMPK, senescence. I’m sure some of these terms are.

Phil Micans [00:53:29]:

Familiar to your listeners, and then how do you address that?

Phil Micans [00:53:34]:

So I find that quite fascinating that.

Phil Micans [00:53:37]:

Perhaps the most powerful thing we have, perhaps for age control might be it’s got to be multifactorial. I think everyone would agree on that is, what are you doing here?

Phil Micans [00:53:50]:

I mean, everyone knows about NAD at the moment, right?

Phil Micans [00:53:52]:

This has been a big thing because of David Sinclair. So you can ask yourself, here are seven steps, what am I doing here?

Phil Micans [00:54:00]:

What am I doing here? What am I doing here? What am I doing here?

Phil Micans [00:54:03]:

What am I doing here?

Phil Micans [00:54:04]:

So that to me, at the moment.

Phil Micans [00:54:07]:

Is very interesting, I guess.

Nick Urban [00:54:09]:

On another related note, if someone’s interested in discovering some of these wow factors, obviously different wow factors, because you’ve now shared and spilled the beans on these ones, what’s your system there? How did you go about finding these?

Phil Micans [00:54:24]:

Well, really old fashioned, if I’m perfectly honest with you.

Phil Micans [00:54:29]:

There’s only a few of us, there’s only a handful of us that actually.

Phil Micans [00:54:31]:

Do the R and D. It’s mainly connections. Imagine after 30 years, I have got to know a lot of people.

Phil Micans [00:54:41]:

Not all of them are with us anymore, unfortunately. I always lose the old saying, standing on the shoulders of giants is very true.

Phil Micans [00:54:50]:

So it’s talking and knowing some really.

Phil Micans [00:54:54]:

Interesting people and meeting with them and sharing with them, that’s a lot of it. And I read the books a few behind me. I’m still a bit old fashioned like that.

Phil Micans [00:55:04]:

Of course, I watch videos online and people, as you network, they tend to send you things, but a lot of.

Phil Micans [00:55:12]:

My interests are very esoteric.

Nick Urban [00:55:15]:

Well, Phil, that’s a good note to end on. Are there any other parting words or thoughts you’d like to leave listeners with today?

Phil Micans [00:55:23]:

Oh, gosh, you’re testing me today, aren’t you?

Nick Urban [00:55:27]:

Yeah.

Phil Micans [00:55:27]:

Be happy. And one thing I found as I got older is don’t worry.

Nick Urban [00:55:37]:

Well, Phil, it’s been a pleasure hosting you again for round two today, and I am definitely looking forward to a follow up show with you. But thanks for spending the time today and sharing these different breakthroughs with us.

Phil Micans [00:55:51]:

You’re welcome, Nick. Always a pleasure. Look forward to the next one.

Nick Urban [00:55:54]:

Until next time. I’m Nick Urban here with Phil Mikens signing out from Mindbodypeak.com. Have a great week and be an outlier.

Nick Urban [00:56:03]:

I hope that this has been helpful for you. If you enjoyed it, subscribe and hit the thumbs up. I love knowing who’s in the 1% committed to reaching their full potential. Comment 1% below so that I know who you are. For all the resources and links, meet me on my website@mindbodypeak.com. I appreciate you and look forward to connecting with you. As a reminder, please tell your primary health professional before making any self changes.